These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37312287)

  • 1. Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction.
    Lauder L; Bergmann MW; Paitazoglou C; Özdemir R; Iliadis C; Bartunek J; Lauten A; Keller T; Weber S; Sievert H; Anker SD; Mahfoud F
    ESC Heart Fail; 2023 Aug; 10(4):2559-2566. PubMed ID: 37312287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction.
    Paitazoglou C; Özdemir R; Pfister R; Bergmann MW; Bartunek J; Kilic T; Lauten A; Schmeisser A; Zoghi M; Anker S; Sievert H; Mahfoud F
    EuroIntervention; 2019 Aug; 15(5):403-410. PubMed ID: 31130524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of atrial flow regulator (AFR) implantation on 12-month mortality in heart failure : Insights from a single site in the PRELIEVE study.
    Bakhshaliyev N; Çelikkale İ; Enhoş A; Karaçöp E; Uluganyan M; Özdemir R
    Herz; 2022 Aug; 47(4):366-373. PubMed ID: 34459929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
    Paitazoglou C; Bergmann MW; Özdemir R; Pfister R; Bartunek J; Kilic T; Lauten A; Schmeisser A; Zoghi M; Anker SD; Sievert H; Mahfoud F;
    Eur J Heart Fail; 2021 May; 23(5):800-810. PubMed ID: 33555114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
    Slee A; Saad M; Saksena S
    J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction.
    Son MK; Park JJ; Lim NK; Kim WH; Choi DJ
    Heart; 2020 Aug; 106(15):1160-1168. PubMed ID: 32341140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
    Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
    ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
    Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
    Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of left atrial appendage closure in atrial fibrillation patients with different types of heart failure.
    Liu L; Yan W; Xu X; Wan C; Liu F; Yao Q; Song L; Wang B; Song Z; Li H
    BMC Cardiovasc Disord; 2024 Aug; 24(1):430. PubMed ID: 39148039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
    Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.
    Kroshian G; Joseph J; Kinlay S; Peralta AO; Hoffmeister PS; Singh JP; Yuyun MF
    J Cardiovasc Electrophysiol; 2024 Apr; 35(4):715-726. PubMed ID: 38348517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics of heart failure with recovered ejection fraction].
    Luo Y; Chai K; Cheng YL; Zhu WR; Li YY; Wang H; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Apr; 49(4):333-339. PubMed ID: 33874682
    [No Abstract]   [Full Text] [Related]  

  • 14. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
    Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
    Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
    Farré N; Lupon J; Roig E; Gonzalez-Costello J; Vila J; Perez S; de Antonio M; Solé-González E; Sánchez-Enrique C; Moliner P; Ruiz S; Enjuanes C; Mirabet S; Bayés-Genís A; Comin-Colet J;
    BMJ Open; 2017 Dec; 7(12):e018719. PubMed ID: 29273666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
    Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of growth differentiation factor-15 in heart failure among whole ejection fraction phenotypes.
    Lyu L; Xu J; Xv C; Xiao H; Liu Z; He Y; Gao W; Hao B; Liu H
    ESC Heart Fail; 2024 Aug; 11(4):2295-2304. PubMed ID: 38641904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study.
    Saksena S; Slee A; Saad M
    J Interv Card Electrophysiol; 2018 Oct; 53(1):9-17. PubMed ID: 29987682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of atrial flow regulator implantation on hemodynamic parameters in patients with heart failure.
    Bakhshaliyev N; Ozdemir R
    Kardiologiia; 2021 Oct; 61(10):71-80. PubMed ID: 34763641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.